Below are the most recent publications written about "Purinergic P2Y Receptor Antagonists" by people in Profiles.
-
Dangelmaier C, Mauri B, Patel A, Kunapuli SP, Kostyak JC. D121 Located within the DRY Motif of P2Y12 Is Essential for P2Y12-Mediated Platelet Function. Int J Mol Sci. 2022 Sep 29; 23(19).
-
Bhatt DL, Kaski JC, Delaney S, Alasnag M, Andreotti F, Angiolillo DJ, Ferro A, Gorog DA, Lorenzatti AJ, Mamas M, McNeil J, Nicolau JC, Steg PG, Tamargo J, Tan D, Valgimigli M. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. Int J Cardiol. 2021 08 15; 337:1-8.
-
Pauley ED, Doorey AJ, Stouffer GA. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in PCI. JACC Cardiovasc Interv. 2019 09 23; 12(18):1867.
-
Sirker A, Kwok CS, Kontopantelis E, Johnson T, Freeman P, de Belder MA, Ludman P, Zaman A, Mamas MA. Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database. Catheter Cardiovasc Interv. 2018 10 01; 92(4):659-665.
-
Branchford BR, Stalker TJ, Law L, Acevedo G, Sather S, Brzezinski C, Wilson KM, Minson K, Lee-Sherick AB, Davizon-Castillo P, Ng C, Zhang W, Neeves KB, Lentz SR, Wang X, Frye SV, Shelton Earp H, DeRyckere D, Brass LF, Graham DK, Di Paola JA. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost. 2018 02; 16(2):352-363.
-
Mizrahi E, Suryadevara RS, Barn K, Boga G, Akram MM, Ismail-Sayed I, Henry YM, Troup MA, Berger PB. Impact of Switching From Prasugrel to Clopidogrel Shortly After a Percutaneous Coronary Intervention Without a Loading Dose of Clopidogrel. J Invasive Cardiol. 2015 Dec; 27(12):543-6.
-
Weeks PA, Sieg A, Paruthi C, Rajapreyar I. Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation. J Cardiovasc Pharmacol Ther. 2015 Jul; 20(4):370-7.
-
Stalker TJ, Traxler EA, Wu J, Wannemacher KM, Cermignano SL, Voronov R, Diamond SL, Brass LF. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood. 2013 Mar 07; 121(10):1875-85.
-
Barn K, Steinhubl SR. A brief review of the past and future of platelet P2Y12 antagonist. Coron Artery Dis. 2012 Sep; 23(6):368-74.
-
Cushing DJ, Souney PF, Cooper WD, Mosher GL, Adams MP, Machatha S, Zhang B, Kowey PR. Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. Clin Exp Pharmacol Physiol. 2012 Jan; 39(1):3-8.